MetaADEDB 2.0 @ LMMD
LDE225
(VZZJRYRQSPEMTK-CALCHBBNSA-N)
Structure
SMILES
C[C@@H]1O[C@H](C)CN(C1)c1ccc(cn1)NC(=O)c1cccc(c1C)c1ccc(cc1)OC(F)(F)F
Type(s)
Approved; Investigational
ATC code(s)
L01XX48
Molecular Formula:
C26H26F3N3O3
Molecular Weight:
485.498
Log P:
5.9595
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
1
TPSA:
63.69
CAS Number(s):
956697-53-3
Synonym(s)
1.
LDE225
2.
N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3-carboxamide
3.
NVP-LDE225
4.
Odomzo
5.
sonidegib
External Link(s)
MeSHC561435
PubChem Compound24775005
BindingDB50394562
ChEBI90863
CHEMBLCHEMBL2105737
DrugBankDB09143
DrugCentral5008
IUPHAR/BPS Guide to PHARMACOLOGY8199
KEGGdr:D10119
Therapeutic Target DatabaseD09BNZ
ZINC68202099
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1FatigueFAERS: 8US FAERS
2AlopeciaFAERS: 6US FAERS
3Drug ineffectiveFAERS: 5US FAERS
4ArthralgiaFAERS: 4US FAERS
5Basal cell carcinomaFAERS: 4US FAERS
6Disease ProgressionFAERS: 4US FAERS
7HeadacheFAERS: 4US FAERS
8NauseaFAERS: 4US FAERS
9VomitingFAERS: 4US FAERS
10Weight decreasedFAERS: 4US FAERS
11AstheniaFAERS: 3US FAERS
12DehydrationFAERS: 3US FAERS
13DysgeusiaFAERS: 3US FAERS
14MyalgiaFAERS: 3US FAERS
15PalpitationsFAERS: 3US FAERS
16PneumoniaFAERS: 3US FAERS
17Therapy cessationFAERS: 3US FAERS
18Abdominal discomfortFAERS: 2US FAERS
19AgeusiaFAERS: 2US FAERS
20Arterial graftFAERS: 2US FAERS
21Chest PainFAERS: 2US FAERS
22ColitisFAERS: 2US FAERS
23Corneal irritationFAERS: 2US FAERS
24DeafnessFAERS: 2US FAERS
25DizzinessFAERS: 2US FAERS
26DyspepsiaFAERS: 2US FAERS
27HypotensionFAERS: 2US FAERS
28InfluenzaFAERS: 2US FAERS
29Malignant neoplasm progressionFAERS: 2US FAERS
30No adverse eventFAERS: 2US FAERS
31PainFAERS: 2US FAERS
32RhinoscleromaFAERS: 2US FAERS
33Therapy changeFAERS: 2US FAERS
34Troponin increasedFAERS: 2US FAERS
35TympanoplastyFAERS: 2US FAERS
36Acute kidney injuryFAERS: 1US FAERS
37AnxietyFAERS: 1US FAERS
38ArthritisFAERS: 1US FAERS
39Atrial FibrillationFAERS: 1US FAERS
40Back PainFAERS: 1US FAERS
41Blood creatine phosphokinase increasedFAERS: 1US FAERS
42Cartilage injuryFAERS: 1US FAERS
43ChillsFAERS: 1US FAERS
44ChokingFAERS: 1US FAERS
45Circumstance or information capable of leading to medication errorFAERS: 1US FAERS
46Concomitant disease aggravatedFAERS: 1US FAERS
47Coronary Artery DiseaseFAERS: 1US FAERS
48DeliriumFAERS: 1US FAERS
49DiverticulitisFAERS: 1US FAERS
50Drug dispensing errorFAERS: 1US FAERS
51Drug dose omissionFAERS: 1US FAERS
52DysuriaFAERS: 1US FAERS
53Gastric ulcerFAERS: 1US FAERS
54Gastrointestinal PainFAERS: 1US FAERS
55General physical health deteriorationFAERS: 1US FAERS
56Head discomfortFAERS: 1US FAERS
57HerniaFAERS: 1US FAERS
58Intestinal ObstructionFAERS: 1US FAERS
59MalaiseFAERS: 1US FAERS
60Musculoskeletal stiffnessFAERS: 1US FAERS
61MyositisFAERS: 1US FAERS
62OsteosclerosisFAERS: 1US FAERS
63Product storage errorFAERS: 1US FAERS
64Product supply issueFAERS: 1US FAERS
65PruritusFAERS: 1US FAERS
66Rash erythematousFAERS: 1US FAERS
67RestlessnessFAERS: 1US FAERS
68Rotator cuff syndromeFAERS: 1US FAERS
69ThrombosisFAERS: 1US FAERS
70Unevaluable eventFAERS: 1US FAERS
71Urinary tract infectionFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.